ERGi-USU-6 (mesylate) is an ERGi-USU-6 salt derivative that is a new selective inhibitor of ERG positive prostate cancer ( IC50 = 0.089 μM).
[1]. Eldhose B, et al. New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. ACS Med Chem Lett. 2021 Oct 19;12(11):1703-1709.
















